Anti-cd98 antibody processes
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsTomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
Life of this patent
Estimating the term…
Loading patent…
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsTomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
Estimating the term…
A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
1-47. (canceled)
An isolated monoclonal antibody or fragment thereof which specifically binds to a CD98 epitope bound by an antibody or fragment thereof that:
An isolated monoclonal antibody or fragment thereof which has:
An isolated monoclonal antibody or fragment thereof which has:
Dependencies are inferred from the claim text.